AVXL vs. XBI
Compare and contrast key facts about Anavex Life Sciences Corp. (AVXL) and SPDR S&P Biotech ETF (XBI).
XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: AVXL or XBI.
Key characteristics
| AVXL | XBI | |
|---|---|---|
| YTD Return | -53.71% | 1.67% |
| 1Y Return | -54.58% | 3.71% |
| 3Y Return (Ann) | -27.06% | -10.59% |
| 5Y Return (Ann) | 4.56% | 1.75% |
| 10Y Return (Ann) | 13.67% | 8.42% |
| Sharpe Ratio | -0.73 | 0.23 |
| Daily Std Dev | 72.25% | 27.88% |
| Max Drawdown | -97.06% | -63.89% |
| Current Drawdown | -85.07% | -47.80% |
Correlation
The correlation between AVXL and XBI is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
AVXL vs. XBI - Performance Comparison
In the year-to-date period, AVXL achieves a -53.71% return, which is significantly lower than XBI's 1.67% return. Over the past 10 years, AVXL has outperformed XBI with an annualized return of 13.67%, while XBI has yielded a comparatively lower 8.42% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
AVXL vs. XBI - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Anavex Life Sciences Corp. (AVXL) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
AVXL vs. XBI - Dividend Comparison
AVXL has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.02%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AVXL Anavex Life Sciences Corp. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
XBI SPDR S&P Biotech ETF | 0.02% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% | 1.07% | 0.17% |
Drawdowns
AVXL vs. XBI - Drawdown Comparison
The maximum AVXL drawdown since its inception was -97.06%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for AVXL and XBI. For additional features, visit the drawdowns tool.
Volatility
AVXL vs. XBI - Volatility Comparison
Anavex Life Sciences Corp. (AVXL) has a higher volatility of 17.30% compared to SPDR S&P Biotech ETF (XBI) at 6.73%. This indicates that AVXL's price experiences larger fluctuations and is considered to be riskier than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.